HIV / AIDS care

Delve into the world of HIV / AIDS care in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on HIV / AIDS care to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

FDA Approves AbbVie's Tavapadon as Juvmo for Parkinson's Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfoli
CompanyDrug

FDA Approves AbbVie’s Tavapadon as Juvmo for Parkinson’s Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfolio

The US Food and Drug Administration (FDA) announced that it has approved AbbVie's (NYSE: ABBV) tavapadon for the treatment of Parkinson's disease, under the brand name Juvmo. Regulatory Milestone ItemDetailAgencyUS…

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers

Biokin's BL-M12D1 Wins NMPA Clinical Trial Approval – ADC Candidate to Be Evaluated as Monotherapy in Relapsed or Refractory Hematologic Malignancies

Biokin’s BL-M12D1 Wins NMPA Clinical Trial Approval – ADC Candidate to Be Evaluated as Monotherapy in Relapsed or Refractory Hematologic Malignancies

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Aidea Pharma’s Novel HIV-1 Capsid Inhibitor ACC085 Cleared for PrEP Trial in China, Targeting Long-Acting Prevention

Company

Gilead Foundation Commits $12 Million to Community Health Worker HIV Prevention Initiative – 33 Organizations Across 15 U.S. Jurisdictions

GSK Reports 7% Revenue Growth to $44.7 Billion in 2025; Oncology Surges 43%
Company

GSK Reports 7% Revenue Growth to $44.7 Billion in 2025; Oncology Surges 43%

Jiangsu Aidea Secures Approval to Launch ADC118 Tablets in China, First Domestic HIV Integrase FDC
CompanyDrug

Jiangsu Aidea Secures Approval to Launch ADC118 Tablets in China, First Domestic HIV Integrase FDC

DaAnGene Secures NMPA Approval for First HIVDNA Diagnostic Kit
CompanyMedical Device

DaAn Gene Secures NMPA Approval for First HIVDNA Diagnostic Kit

Gilead’s Yeytuo Gains EU Marketing Authorization for Twice‑Yearly HIV‑1 PrEP
CompanyDrug

Gilead’s Yeytuo Gains EU Marketing Authorization for Twice‑Yearly HIV‑1 PrEP

Merck Initiates EXPrESSIVE Phase III Trial for Once-Monthly HIV PrEP Drug MK-8527
CompanyDrug

Merck Initiates EXPrESSIVE Phase III Trial for Once-Monthly HIV PrEP Drug MK-8527

MSD's Once-Daily HIV-1 Therapy Doravirine/Islatravir NDA Accepted by FDA for Review
CompanyDrug

MSD’s Once-Daily HIV-1 Therapy Doravirine/Islatravir NDA Accepted by FDA for Review

Show More